Kura Oncology, Inc. (NASDAQ:KURA) shares are trading higher Tuesday after the company reported preliminary clinical data from the first 20 patients in its Komet-007 Phase 1 dose-escalation trial.
The Details:
Kura Oncology reported that all newly diagnosed patients treated with ziftomenib and 7+3 achieved a complete remission (CR) with full count recovery, for a CR rate of 100% (5/5), including four patients with NPM1-m acute myeloid leukemia (AML) and one patient with KMT2A-r AML.
“We are highly encouraged by these preliminary combination data for ziftomenib and believe they support advancement into the frontline AML population,” said Troy Wilson, Ph.D., J.D., President and Chief ...